← Back to Search

Stem Cell Therapy

Stem Cell Therapy + Exoskeleton/Virtual Reality for Spinal Cord Injury (SciExVR Trial)

N/A
Waitlist Available
Led By Jeffrey Weiss, MD
Research Sponsored by MD Stem Cells
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Have documented functional damage to the spinal cord unlikely to improve with present standard of care.
Have documented functional damage to the spinal cord unlikely to improve with present standard of care
Must not have
Patients must be capable of providing informed consent.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1,3,6,12 months post-procedure
Awards & highlights
No Placebo-Only Group

Summary

This trial is investigating whether autologous bone marrow derived stem cells can help improve motor or sensory function in people with spinal cord injury. The treatment involves injections of the cells around the area of the injury, as well as an intravenous injection and intranasal placement. Patients may also be assigned to use exoskeletal movement or virtual reality visualization to help improve function.

Who is the study for?
Adults over 18 with spinal cord injuries that are stable and unlikely to improve with current treatments can join this trial. They must be medically cleared, able to give consent, and not at significant risk from the procedure. Pregnant women or those planning pregnancy within 3 months post-treatment cannot participate.
What is being tested?
The study tests bone marrow stem cells injected near the injury site, followed by intravenous and intranasal placement. Participants may also use an exoskeleton or virtual reality to potentially enhance nerve function.
What are the potential side effects?
Possible side effects include discomfort at injection sites, infection risk from injections, allergic reactions to stem cells, and potential unknown risks associated with stem cell therapy.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My spinal cord injury is not expected to get better with current treatments.
Select...
My spinal cord injury is not expected to improve with current treatments.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I am able to understand and agree to the study's procedures and risks.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1,3,6,12 months post-procedure
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1,3,6,12 months post-procedure for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
American Spinal Injury Association (ASIA) Impairment Scale (AIS)
Secondary study objectives
Autonomic Nervous System (ANS) Function
General Well-Being

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

3Treatment groups
Experimental Treatment
Group I: Paraspinal VRExperimental Treatment2 Interventions
Bilateral paraspinal injection of bone marrow derived stem cells (BMSC) at spinal cord injury level, superior to injury level and inferior to injury level. Following paraspinal injection remaining BMSC provided intravenous and intranasal. Virtual Reality or equivalent visualization following this treatment.
Group II: Paraspinal EXExperimental Treatment2 Interventions
Bilateral paraspinal injection of bone marrow derived stem cells (BMSC) at spinal cord injury level, superior to injury level and inferior to injury level. Following paraspinal injection remaining BMSC provided intravenous and intranasal. Exoskeleton or equivalent stimulation following this treatment.
Group III: ParaspinalExperimental Treatment1 Intervention
Bilateral paraspinal injection of bone marrow derived stem cells (BMSC) at spinal cord injury level, superior to injury level and inferior to injury level. Following paraspinal injection remaining BMSC provided intravenous and intranasal.

Find a Location

Who is running the clinical trial?

MD Stem CellsLead Sponsor
5 Previous Clinical Trials
1,450 Total Patients Enrolled
Steven Levy, MDStudy ChairMD Stem Cells
4 Previous Clinical Trials
1,400 Total Patients Enrolled
Jeffrey Weiss, MDPrincipal InvestigatorCoral Springs
4 Previous Clinical Trials
1,400 Total Patients Enrolled

Media Library

Autologous Bone Marrow Derived Stem Cells (Stem Cell Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT03225625 — N/A
Spinal Cord Injury Research Study Groups: Paraspinal, Paraspinal EX, Paraspinal VR
Spinal Cord Injury Clinical Trial 2023: Autologous Bone Marrow Derived Stem Cells Highlights & Side Effects. Trial Name: NCT03225625 — N/A
Autologous Bone Marrow Derived Stem Cells (Stem Cell Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03225625 — N/A
Spinal Cord Injury Patient Testimony for trial: Trial Name: NCT03225625 — N/A
~3 spots leftby Jul 2025